NCT00788580撤回1 期
S0718: Phase I Study Evaluating The Combination of GW786034 (Pazopanib; NSC-737754; IND-XXXX) and CCI-779 (Temsirolimus; NSC-683864; IND-XXXX) in Patients With Advanced Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Safety as assessed by NCI CTCAE v3.0
研究概览
简要总结
RATIONALE: Pazopanib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib may also blocking blood flow to the tumor. Giving pazopanib together with temsirolimus may be an effective treatment for advanced solid tumors.
PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus when given together with pazopanib in treating patients with advanced solid tumors.
详细描述
OBJECTIVES:
- To investigate the safety and feasibility of temsirolimus and pazopanib when given in combination in patients with advanced solid tumors.
- To recommend the maximum tolerated dose of this regimen in these patients.
- To investigate the pharmacokinetics of temsirolimus alone and in combination with pazopanib in these patients.
- To investigate the effects of this regimen on relevant biological markers.
- To preliminarily report objective response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral pazopanib hydrochloride once daily on days 4-28 in course 1 and days 1-28 in all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood samples are obtained periodically for evaluation of the pharmacokinetics of temsirolimus and pazopanib, plasma and serum angiogenic and cachectic factors (e.g., VEGF, bFGF, PlGF and SDF-1) by enzyme-linked immunosorbent assay, and biological markers in the mTOR/PI3/Akt, Ras/MAPK, VEGFR, PDGFR, and HIF-1 pathways.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Cytologically or pathologically verified cancer that is of advanced stage and for which there is no effective therapy
- •No lymphoma
- •Measurable or nonmeasurable disease
- •Previously irradiated (whole brain or gamma knife) brain metastases allowed provided there is no requirement for corticosteroids or anticonvulsants
- •PATIENT CHARACTERISTICS:
- •Zubrod performance status 0-2
- •ANC ≥ 1,500/mm³
- •Platelet count ≥ 100,000/mm³
- •Hemoglobin ≥ 9 g/dL (without transfusions)
- •AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver metastases present)
- •Bilirubin normal
- •Serum creatinine ≤ 1.5 times ULN OR measured creatinine clearance OR calculated creatinine clearance ≥ 60 mL/min
- •QTC interval < 480 msec on baseline ECG OR average QTC < 480 msec on baseline plus 2 additional screening ECG's
- •Fasting cholesterol < 350 mg/dL
- •Fasting triglycerides < 400 mg/dL
- •No uncontrolled hypertension, arterial thrombotic event, or bleeding on therapeutic anticoagulation with warfarin or heparin (including low molecular weight heparin) within the past 6 months
- •Able to swallow enteral medications
- •No feeding tubes
- •No intractable nausea or vomiting
- •No gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn, ulcerative colitis)
- •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to rapamycin analogs (e.g., sirolimus and everolimus)
- •No known HIV positivity
- •No uncontrolled intercurrent illness including, but not limited to, the following:
- •Ongoing or serious active infection
- •Symptomatic congestive heart failure
- •Unstable angina pectoris
- •Serious cardiac arrhythmia
- •History of myocardial infarction
- •Cerebrovascular accident within 3 months of study entry
- •Uncontrolled diarrhea
- •Psychiatric illness or social situation that would limit compliance with study requirements
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception, including barrier methods
- •Willing to undergo pharmacokinetic (PK) sampling and blood submission for PK and translational medicine studies
- •PRIOR CONCURRENT THERAPY:
- •Recovered from all prior therapy
- •No prior pazopanib hydrochloride or temsirolimus
- •More than 28 days since prior major surgery, chemotherapy, biologic therapy, or immunotherapy
- •More than 28 days since prior investigational agents
- •At least 14 days since prior radiotherapy
- •No concurrent rapamycin (sirolimus)
- •No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), CYP3A4 inducers (e.g., rifampin or St. John's wort), or CYP3A4 inhibiting agents or substrates (e.g., ketoconazole, diltiazem, or verapamil)
- •No concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of this cancer while on this protocol
- •No live vaccines
- •Luteinizing-hormone releasing-hormone agonists allowed
- •Concurrent prophylactic warfarin (≤ 1 mg/day) allowed
- •Concurrent bisphosphonate or erythropoietin or its analogue allowed, if deemed appropriate by the treating physician
排除标准
- 未提供
结局指标
主要结局
Safety as assessed by NCI CTCAE v3.0
Feasibility of the drug combination
Maximum tolerated dose of temsirolimus in combination with pazopanib
次要结局
- Pharmacokinetics of temsirolimus alone and in combination with pazopanib
- Relevant biological markers
- Objective response as assessed by RECIST criteria
研究者
相似试验
已完成
1 期
Temsirolimus and Pazopanib in Patients With Advanced Solid TumorsSolid TumorsNCT01072890University of California, Davis8
已完成
1 期
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to ChemotherapyProstate CancerNCT01083368Case Comprehensive Cancer Center22
终止
1 期
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue SarcomaBrain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol SpecificNeuroblastomaSarcomaNCT01204450UNC Lineberger Comprehensive Cancer Center7
已完成
1 期
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmLymphomaNCT00962507City of Hope Medical Center11
已完成
1 期
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsStage III Neuroendocrine Carcinoma of the SkinExtensive Stage Small Cell Lung CancerMalignant ParagangliomaRecurrent Breast CancerRecurrent Cervical CancerRecurrent Endometrial CarcinomaStage III Ovarian Epithelial CancerStage IV Endometrial CarcinomaStage IV Neuroendocrine Carcinoma of the SkinStage IV Non-small Cell Lung CancerStage IVA Cervical CancerRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaRecurrent Neuroendocrine Carcinoma of the SkinRecurrent Ovarian Epithelial CancerRecurrent Prostate CancerRegional Gastrointestinal Carcinoid TumorRegional PheochromocytomaStage III Cervical CancerStage III Uterine SarcomaRecurrent Small Cell Lung CancerStage III Prostate CancerStage III Renal Cell CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IVB Cervical CancerThyroid Gland Medullary CarcinomaMale Breast CancerHereditary ParagangliomaMetastatic Gastrointestinal Carcinoid TumorRecurrent Non-small Cell Lung CancerMetastatic PheochromocytomaRecurrent PheochromocytomaRecurrent Renal Cell CancerRecurrent Uterine SarcomaStage III Endometrial CarcinomaStage III Ovarian Germ Cell TumorStage IIIA Non-small Cell Lung CancerPancreatic Polypeptide TumorRecurrent Ovarian Germ Cell TumorStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell TumorStage IIIB Non-small Cell Lung CancerStage IIIC Breast CancerStage IV Breast CancerStage IV Prostate CancerStage IV Renal Cell CancerStage IV Uterine SarcomaNCT01155258University of Southern California19